Loading...
•
Sep 30, 2024
Teva Q3 2024 Earnings Report
Reported strong financial results led by Generics performance and Innovative portfolio growth.
Key Takeaways
Teva Pharmaceutical Industries Ltd. reported a strong third quarter of 2024, marking the seventh consecutive quarter of growth with global revenues reaching $4.3 billion, a 15% increase in local currency terms compared to the third quarter of 2023. The company's innovative portfolio and generics business drove this performance, leading to an increased 2024 financial outlook, including revenues, Adjusted EBITDA, and Non-GAAP EPS.
Global revenues reached $4.3 billion, a 15% increase in local currency terms compared to Q3 2023.
Innovative portfolio and generics business drove strong performance.
Raised 2024 financial outlook, including on revenues, Adjusted EBITDA, and Non-GAAP EPS.
Launched octreotide acetate for injectable suspension, the first generic version of Sandostatin LAR Depot.
Teva
Teva
Teva Revenue by Segment
Teva Revenue by Geographic Location
Revenue by Segment
United States Revenue
CapyFin.comEurope Revenue
CapyFin.comInternational Markets Revenue
CapyFin.comOther Activities Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comEurope Revenue
CapyFin.comInternational Markets Revenue
CapyFin.com Forward Guidance
Teva raised its 2024 financial outlook, including on revenues, Adjusted EBITDA, and Non-GAAP EPS.
Positive Outlook
- Revenues: $16.1 - $16.5 billion
- AUSTEDO: ~$1.6 billion
- AJOVY: ~$500 million
- UZEDY: ~$100 million
- Free Cash Flow: $1.7 - $2.0 billion
Challenges Ahead
- COPAXONE: ~$500 million
- Operating Income: $4.2 - $4.5 billion
- Adjusted EBITDA: $4.7 - $5.0 billion
- Finance Expenses: ~$1.0 billion
- Tax Rate: 14% - 17%
Revenue & Expenses
Visualization of income flow from segment revenue to net income